<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35479117</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2666-1667</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>3</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>STAR protocols</Title>
          <ISOAbbreviation>STAR Protoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Combined micro-osmotic pump infusion and intracerebroventricular injection to study FGF1 signaling pathways in the mouse brain.</ArticleTitle>
        <Pagination>
          <StartPage>101329</StartPage>
          <MedlinePgn>101329</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101329</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xpro.2022.101329</ELocationID>
        <Abstract>
          <AbstractText>Intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) elicits remission of diabetic hyperglycemia in rodent models of type 2 diabetes. Here, we present an optimized protocol to study the intracellular signaling pathways underlying the FGF1-induced sustained glucose lowering in the mouse brain. This protocol combines icv injection of FGF1 and osmotic mini-pump infusion of U0126, an inhibitor of MAPK/ERK signaling. We describe the surgical procedure and verification of U0126 inhibition of FGF1-stimulated hypothalamic MAPK/ERK signaling via western blot. For complete details on the use and execution of this protocol, please refer to Brown et al. (2021).</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Jenny M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Phan</LastName>
            <ForeName>Bao Anh</ForeName>
            <Initials>BA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aalling</LastName>
            <ForeName>Nadia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morton</LastName>
            <ForeName>Gregory J</ForeName>
            <Initials>GJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwartz</LastName>
            <ForeName>Michael W</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scarlett</LastName>
            <ForeName>Jarrad M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, University of Washington Medicine Diabetes Institute, 750 Republican St, F770, Seattle, WA 98109, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA 98145, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>STAR Protoc</MedlineTA>
        <NlmUniqueID>101769501</NlmUniqueID>
        <ISSNLinking>2666-1667</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>104781-85-3</RegistryNumber>
          <NameOfSubstance UI="D016220">Fibroblast Growth Factor 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016220" MajorTopicYN="Y">Fibroblast Growth Factor 1</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Metabolism</Keyword>
        <Keyword MajorTopicYN="N">Model Organisms</Keyword>
        <Keyword MajorTopicYN="N">Molecular Biology</Keyword>
        <Keyword MajorTopicYN="N">Neuroscience</Keyword>
        <Keyword MajorTopicYN="N">Signal Transduction</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35479117</ArticleId>
        <ArticleId IdType="pmc">PMC9035806</ArticleId>
        <ArticleId IdType="doi">10.1016/j.xpro.2022.101329</ArticleId>
        <ArticleId IdType="pii">S2666-1667(22)00209-X</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bentsen M.A., Rausch D.M., Mirzadeh Z., Muta K., Scarlett J.M., Brown J.M., Herranz-Pérez V., Baquero A.F., Thompson J., Alonge K.M., et al.  Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission. Nat. Commun. 2020;11:4458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7477234</ArticleId>
            <ArticleId IdType="pubmed">32895383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J.M., Bentsen M.A., Rausch D.M., Phan B.A., Wieck D., Wasanwala H., Matsen M.E., Acharya N., Richardson N.E., Zhao X., et al.  Role of hypothalamic MAPK/ERK signaling and central action of FGF1 in diabetes remission. iScience. 2021;24:102944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8368994</ArticleId>
            <ArticleId IdType="pubmed">34430821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J.M., Scarlett J.M., Matsen M.E., Nguyen H.T., Secher A.L., Jorgensen R., Morton G.J., Schwartz M.W. The hypothalamic arcuate nucleus–median eminence is a target for sustained diabetes remission induced by fibroblast growth factor 1. Diabetes. 2019;68:1054–1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6477902</ArticleId>
            <ArticleId IdType="pubmed">30796029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarlett J.M., Muta K., Brown J.M., Rojas J.M., Matsen M.E., Acharya N.K., Secher A., Ingvorsen C., Jorgensen R., Høeg-Jensen T., et al.  Peripheral mechanisms mediating the sustained antidiabetic action of FGF1 in the brain. Diabetes. 2019;68:654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6385755</ArticleId>
            <ArticleId IdType="pubmed">30523024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scarlett J.M., Rojas J.M., Matsen M.E., Kaiyala K.J., Stefanovski D., Bergman R.N., Nguyen H.T., Dorfman M.D., Lantier L., Wasserman D.H., et al.  Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat. Med. 2016;22:800–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4938755</ArticleId>
            <ArticleId IdType="pubmed">27213816</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
